I’m not in the lead with regard to the research but one advantage of the fund is that we can take room for more funding into account. E.g. we think very highly of CORRECTIV but since they recently got a lot of (well deserved) attention their room to use additional funds might be limited very soon (might already be the case).
I’m not in the lead with regard to the research but one advantage of the fund is that we can take room for more funding into account. E.g. we think very highly of CORRECTIV but since they recently got a lot of (well deserved) attention their room to use additional funds might be limited very soon (might already be the case).